Samsung Biologics moves to acquire PolyPeptide CDMO in $1.8B peptide play REPORTED

Samsung Biologics announced an all-cash offer for PolyPeptide Group, one of the larger peptide CDMOs, at roughly $1.8B, expected to close near the end of 2026 (fiercepharma.com).

It is the largest takeover in South Korea's biopharma history: six sites across five countries and a peptide-specialized workforce, aimed at the GLP-1 and obesity supply chain. Eli Lilly is separately expanding its own peptide capacity.

The deal lands two days before FDA's PCAC meeting (July 23-24), which is advisory only and changes nothing about what can legally be compounded.

The operator signal is where the capital is going. Big pharma is pouring money into approved-drug peptide manufacturing, well upstream of the compounding lane, and that shapes your long-term sourcing, pricing, and which products reps push into your market.

Do this next. Which of your peptide lines actually depend on compounded supply? List them, split compounded versus approved, and price out what a forced switch to the approved channel does to each.

FDA to Review Peptides: What Med Spa Professionals Should Know Ahead of the July 23-24 Meeting REPORTED

The American Med Spa Association briefed its members on July 22 ahead of FDA's Pharmacy Compounding Advisory Committee meeting (July 23-24), which weighs whether several peptides belong on the Section 503A bulks list (americanmedspa.org).

AmSpa gets the framing right: the vote is advisory. It does not approve or ban anything, and it does not change what a 503A pharmacy can compound the day after.

The real signal is who is covering it. When the largest med spa trade group briefs its full membership, the buyers themselves are watching PCAC, and they will move the story faster than the pharmacies do.

Expect the results repeated, summarized, and mangled across thousands of clinic marketing channels within days, whichever way the committee votes.

Do this next. Your staff will field PCAC questions by Friday. Write a three-sentence internal script today, before the vote, so everyone answers with "advisory recommendation, nothing legally changed" instead of improvising.

Ex-LifeMD employees allege rushed clinical oversight on GLP-1 telehealth RUMORED

Ex-LifeMD employees, including a former COO, allege the telehealth company rushes intake and drops clinical oversight once patients are on GLP-1s, per STAT reporting flagged by reporter Isabella Cueto (x.com).

These are ex-employee allegations reported by STAT. No regulator has made findings, and LifeMD's response is in the full piece.

The relevance runs past LifeMD to the pattern it sets: named-source insider accounts of thin GLP-1 oversight are exactly what state medical boards and plaintiff attorneys read, and every high-volume prescriber gets measured against the worst story in circulation.

Do this next. Would your intake read like the allegations? Pull your GLP-1 follow-up protocol (labs, weight checks, documented touchpoints after initiation) and make sure the record shows the oversight you claim.

JAMA Health Forum: clinics and med spas still sell compounded GLP-1 from unlicensed pharmacies. Despite the federal shortage ending, a new study finds sellers sourcing from pharmacies that lack sterile-compounding licenses or face disciplinary action (reddit.com).

A trial tests fasting guidance for patients on GLP-1s. Registered study of whether fasting recommendations change outcomes for GLP-1 receptor agonist patients (clinicaltrials.gov).

Another semaglutide obesity trial enters the pipeline. A registered study of semaglutide for weight management (clinicaltrials.gov).

Tirzepatide gets tested for hidradenitis suppurativa. A registered trial pushing tirzepatide into an inflammatory-skin indication, an off-label direction worth watching (clinicaltrials.gov).

Does tirzepatide interfere with birth control pills? A pharmacokinetic study on oral contraceptive levels, a real counseling question for clinics prescribing to women (clinicaltrials.gov).